What is petrelintide, and how does the amylin analog compare to GLP-1 drugs?

The short answer

Petrelintide is Zealand Pharma's long-acting amylin analog, partnered with Roche and now heading to Phase 3. In its Phase 2 trial it produced about 10.7% mean body-weight loss at 42 weeks versus 1.7% on placebo — but the headline isn't the number, it's the tolerability: at the most effective dose there were reportedly no cases of vomiting and no discontinuations from GI side effects. That's the problem it's trying to solve.

Evidence tier: Tier 1 for the Phase 2 weight-loss result; Tier 2 for the tolerability claim (topline/company-reported, pending full publication). Educational content, not medical advice.

The key points:

• Amylin analog — a different satiety pathway from GLP-1
• ~10.7% weight loss at 42 weeks in Phase 2 vs 1.7% placebo
• The real story is tolerability — reportedly no vomiting at the top effective dose
• Not approved — Phase 3 with Roche; anything sold online is fake

For the amylin class, see cagrilintide explained.

What is petrelintide?

Evidence tier: 2 — established pharmacology.

Petrelintide (development code ZP8396) is a long-acting amylin analog given as a once-weekly subcutaneous injection, developed by Zealand Pharma and, since a 2025 collaboration, co-developed with Roche. Amylin is a hormone co-secreted with insulin that promotes satiety — a genuinely different appetite pathway from the GLP-1 route used by semaglutide and tirzepatide. Beyond simply signalling fullness, amylin-receptor activation appears to restore sensitivity to leptin, the hormone that regulates long-term energy balance, which is part of why the class is considered such an interesting target (amylin as a future obesity treatment).

Petrelintide sits alongside Novo's cagrilintide as one of the two leading amylin analogs (Lau et al. 2021, cagrilintide Phase 2). The strategic difference is emphasis: cagrilintide's most prominent development is as part of a combination (CagriSema, with semaglutide), whereas petrelintide is being advanced as an amylin monotherapy — a standalone weight-management drug rather than an add-on. Roche's involvement signals serious belief that amylin alone can be a foundational obesity therapy, not just a GLP-1 partner.

How much weight loss does petrelintide produce?

Evidence tier: 1 — Phase 2 randomized trial.

The pivotal data come from ZUPREME-1, a randomized, double-blind, placebo-controlled, multinational Phase 2 dose-finding trial in 485 adults with obesity or overweight with weight-related comorbidities, testing five once-weekly doses of petrelintide against placebo (ClinicalTrials.gov NCT06662539). The trial met its primary endpoint, with statistically significant and clinically meaningful weight reduction at 28 weeks across all five dose arms versus placebo. Extending out, participants achieved mean weight loss of about 10.7% from baseline at 42 weeks, compared with roughly 1.7% on placebo.

Put in context: ~10.7% is a solid, clinically meaningful result — comparable to the amylin monotherapy figures seen with cagrilintide, and a real amount of weight for most people. In cross-trial terms it sits below the peak numbers reported for tirzepatide or retatrutide, though those comparisons are not head-to-head and involve different populations, durations, and designs. But focusing only on the percentage misses what makes petrelintide interesting — because the thing that has drawn the most attention isn't how much weight came off, it's what didn't happen along the way.

The real story: tolerability

Evidence tier: 2 — topline/company-reported, pending full publication.

Here's why petrelintide generated outsized attention. The single biggest real-world problem with GLP-1 drugs isn't efficacy — it's tolerability: nausea, vomiting, and GI distress are common, they're the main reason people fail to reach or stay at effective doses, and they drive a meaningful share of discontinuations. Petrelintide's Phase 2 reported "placebo-like tolerability," and specifically that at the maximally effective dose there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events. If that holds up, it addresses the exact failure point of the current standard of care.

Two honest caveats. First, this is topline, company-reported characterization from a Phase 2 trial — the full peer-reviewed dataset and Phase 3 experience will determine whether "placebo-like" survives contact with larger, longer, real-world use. Companies describe their own results favorably, and that's worth remembering. Second, tolerability claims can look better in a trial population than in general practice. Still, "no vomiting at the effective dose" is a striking claim in this class, and it points at a genuine potential niche: people who want meaningful weight loss but can't tolerate GLP-1 side effects — a large, underserved group. That's a more interesting proposition than simply competing on the biggest percentage.

How does petrelintide compare to the GLP-1 drugs?

Evidence tier: 2 — cross-trial comparison, not head-to-head.

Mechanistically, petrelintide is doing something different: amylin, not GLP-1. That matters both for the side-effect profile (GI effects seem milder via the amylin route) and for combination potential — amylin stacks additively with GLP-1, which is the logic behind CagriSema and the unimolecular amycretin. On raw efficacy, cross-trial figures put petrelintide's ~10.7% below tirzepatide and retatrutide peaks and roughly in line with other amylin monotherapy; on tolerability, it may lead the field. So the honest positioning is not "the strongest weight-loss drug" but potentially "comparable-enough weight loss with far better tolerability."

It's worth being precise about why tolerability translates into real-world results rather than just comfort. Weight loss on any of these drugs is dose-dependent, so a person who stalls at a low dose because higher doses make them sick doesn't get the drug's full benefit — and someone who quits entirely gets none of it and typically regains. A slightly lower peak efficacy that people can actually reach and sustain can therefore outperform a higher peak that many can't tolerate.

Whether that's the more valuable proposition depends on the person. For someone who tolerates a GLP-1 and wants maximum weight loss, the incretin drugs remain ahead. For the substantial group who quit GLP-1s because of nausea and vomiting — or who never reach an effective dose — a drug delivering double-digit loss without those effects could be transformative. That's why Roche partnered on it and why it's moving to Phase 3 for chronic weight management, with a second trial (ZUPREME-2) evaluating it in people with overweight/obesity and type 2 diabetes (NCT06926842). For the wider landscape, see the next-gen multi-agonists overview.

Can you get petrelintide?

Evidence tier: 1–2 — regulatory status.

No. Petrelintide is investigational and not approved anywhere. Its most advanced evidence is Phase 2, with Phase 3 underway — meaning it's realistically years from any pharmacy shelf, assuming the Phase 3 program succeeds and clears regulatory review. There is no legitimate route to obtain it as a patient outside a clinical trial, and anything sold online as "petrelintide" is gray-market and almost certainly not the genuine compound, carrying the usual authenticity, purity, dosing, and sterility risks of any unregulated injectable (spotting counterfeit peptides).

For anyone whose actual goal is weight loss now, the practical answer is unchanged: the approved GLP-1 therapies used under medical supervision, plus the fundamentals, are what's available and proven. Petrelintide's significance is about where obesity treatment is heading — specifically, the possibility that the next meaningful advance is not "more weight loss" but "the same weight loss people can actually stay on." If the tolerability advantage holds through Phase 3, that reframes what a good obesity drug looks like. Watch the ZUPREME-2 readout and the Phase 3 program; don't buy the name online.

Limitations

This is educational content, not medical advice.

• Efficacy data are Phase 2 — promising and endpoint-met, but not confirmatory; Phase 3 is ongoing.
• The tolerability claim is topline/company-reported — the full peer-reviewed and Phase 3 data will test it.
• Cross-trial comparisons aren't head-to-head — don't directly rank petrelintide vs tirzepatide/retatrutide.
• Not approved anywhere — no legitimate access outside a trial; online "petrelintide" is fake.
• Longer-term safety and durability of amylin monotherapy are still being established.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Petrelintide is Zealand and Roche's long-acting amylin analog, and its Phase 2 result — roughly 10.7% mean weight loss at 42 weeks versus 1.7% on placebo — is solid without topping the incretin leaders. The reason it matters is tolerability: the trial reported placebo-like tolerability, with no vomiting and no GI-driven discontinuations at the most effective dose. Since nausea and vomiting are precisely why many people abandon GLP-1 drugs or never reach an effective dose, a drug that delivers double-digit weight loss without them could serve a large underserved group. Those tolerability claims are still topline and need Phase 3 confirmation, and the drug is years from approval — so treat petrelintide as one of the most interesting names to watch in obesity medicine, not something to seek out today.

Related on this site

• Cagrilintide: the amylin analog explained
• Amycretin (GLP-1/amylin) explained
• CagriSema deep-dive
• Next-gen multi-agonists overview
• Managing GLP-1 side effects
• Our evidence-tier framework

References

• ZUPREME-1: Phase 2 dose-finding trial of petrelintide in overweight/obesity. ClinicalTrials.gov NCT06662539 — trial design, population, endpoints.
• ZUPREME-2: Petrelintide in participants with overweight or obesity and type 2 diabetes. ClinicalTrials.gov NCT06926842 — ongoing diabetes program.
• Lau DCW, et al. 2021. Once-weekly cagrilintide for weight management: a phase 2 trial. Lancet. PMID 34798060 — amylin monotherapy benchmark.
• Amylin as a future obesity treatment (review). PMC8735818 — amylin biology and leptin sensitivity.